馃敼 EPS: $0.23
馃敼 Revenue: $866.4M (Est. $807.16M) 馃煝; UP +47% YoY
FY25 Outlook:
馃敼 Revenue: $3.13B-$3.19B (Est. $3.093B) 馃煝
馃敼 Adjusted Operating Margin: Expected at 22.5%-23.5%
Q3 Guidance :
馃敼 Revenue: $755M-$785M (Est. $772.03M) 馃煛
馃敼 GMV: $8.0B-$8.3B
馃敼 GAAP Operating Income: Expected to turn profitable in Q4 FY25
Key Business Metrics:
馃敼 Interest Income: $409.4M (Est. $414.17M) 馃煛; UP +42% YoY
馃敼 Gain on Sale of Loans: $125.3M (Est. $72.25M) 馃煝; UP +138% YoY
馃敼 Gross Merchandise Volume (GMV): $10.1B; UP +35% YoY
馃敼 Total Network Revenue: $303M; UP +33% YoY
馃敼 Active Consumers: 21M; UP +23% YoY
馃敼 Active Merchants: 337,000; UP +21% YoY
馃敼 Transactions per Active Consumer: 5.3 (Prev. 4.4)
Profitability & Financials:
馃敼 Operating Loss: ($4.3M) (Prev. -$172.2M); Improved significantly
馃敼 Net Income: $80.4M (Prev. -$166.9M loss)
馃敼 Adjusted Operating Income: $237.8M (Prev. $92.6M)
馃敼 Total Liquidity: $1.9B at quarter-end
馃敼 Funding Capacity: Increased to $22.6B (Prev. $16.8B in Q1)
Business & Strategic Highlights:
馃敻 UK Expansion: Launched in the UK with positive early results
馃敻 GoodRx Partnership: Introduced medication financing
馃敻 Affirm Card Growth: GMV more than doubled to $845M; 1.7M active cardholders
CEO Max Levchin's Commentary:
馃敻 "Affirm is in the strongest shape it鈥檚 ever been. We鈥檝e met challenges, bested competitors, and continue to see excellent growth in our rapidly expanding segment with strong operating leverage."